STAT5A and acute lymphoblastic leukemia: Indeed, this antagonism may largely explain the tumor suppressor function of Ikaros in BCP-ALL, where IKZF1 loss-of-function mutations are most prevalent in subtypes exhibiting activated JAK/STAT5 signaling.